AstraZeneca trumpets the 'momentous' data they found for Tagrisso in an adjuvant setting for NSCLC — but many of the experts aren’t cheering along
AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.
Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 91,900+ biopharma pros reading Endpoints daily — and it's free.